NCT00496327View on ClinicalTrials.gov

Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 22, 2005

Primary Completion Date

October 6, 2005

Study Completion Date

October 6, 2005

Conditions

Varicella

Interventions

BIOLOGICAL

Varicella Virus Vaccine Live (Oka-Merck)

VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00496327 - Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) | Biotech Hunter | Biotech Hunter